ince stent thrombosis (ST) is one of the serious and mortal complications after percutaneous coronary intervention (PCI), especially drug-eluting stent (DES) implantation, we are eager that the means of predicting and preventing ST be established. Several studies have reported an association between inflammation and stent thrombogenicity. In a clinical setting, Hwang et al1 reported a positive ...

Background—Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring 1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). Methods and Results—We assessed the risk of stent thrombosis in a coho...

BACKGROUND There are limited data on the frequency of and factors associated with quantitative coronary angiography (QCA)-defined longitudinal stent deformation (LSD) in various contemporary drug-eluting stents platforms. This study sought to evaluate the predictors of LSD and its long-term clinical implication. METHODS AND RESULTS A patient-level pooled analysis was performed with 7350 lesio...

Objective: To determine the frequency of acute stent thrombosis after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Study Design: Descriptive cross sectional study. Place and Duration Study: Department Cardiology, National Institute Cardiovascular Disease Hospital, Karachi from 30th 2017 to 31st December 2017. Methodology: One hundred sixty thre...

OBJECTIVES The aim of this study was to assess the safety and efficacy of the implantation of Resolute zotarolimus-eluting stents (ZES) (Medtronic Inc., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months. BACKGROUND Only limited long-term follow-up ...

Drug-eluting stents (DES) have reduced the rate of repeated revascularization of target lesions. For this reason, DES are considered to be superior to bare-metal stents in reducing the restenosis rate. However, some problems have been reported after implantation of DES. One of them, stent thrombosis, has arisen as a fatal complication. Dual antiplatelet therapy is recommended for at least 12 mo...

We now have at our disposal a variety of new technologies for percutaneous coronary revascularization, including drug-eluting stents (DES), intracoronary radiation therapy, and glycoprotein IIb/IIIa inhibitors. Coronary stents have improved both early and late outcomes following percutaneous coronary intervention. Stent characteristics including design, stent strut thickness, and stent metal al...

While drug eluting stents (DES) are being more widely used in ever more patients receiving DES each day, some new complications may be emerging. Stent fractures and hypersensitivity reactions to stents are among recognized complications that can lead to therapeutic dead end from the interventional cardiologist's point of view. We present a case in which we reached therapeutic dead end with a si...

OBJECTIVES We conducted this trial to assess whether a sirolimus-eluting stent (SES) produces similar results to a paclitaxel-eluting stent (PES) when used in the real world of interventional cardiology. BACKGROUND Several drug-eluting stents have been shown to exert a beneficial effect on restenosis when used in the treatment of coronary artery disease. Any potential superiority of one drug ...